바이오하베스트 사이언스BHST 주가

♻️ 재탕[6-K] 6-K — REPORT

BioHarvest Sciences and Tate & Lyle expand sweetener development program

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) announced that it has expanded its collaboration with Tate & Lyle PLC (LSE:TATE) to broaden the scope of their joint sweetener development program to include multiple plant-based sweetener molecules. The expanded partnership builds on an...

♻️ 재탕BioHarvest (BHST) Q1 2026 Earnings Transcript

Zaki Rakib: Thank you, Dory, and thank you all for joining us this morning. BioHarvest Sciences is an industrial plant cell culture biotech company and a leader in Botanical Synthesis, which is a patented non-GMO platform technology that industrializes what nature otherwise does slowly and produces high-value plant-derived compounds and botanical compositions without growing the plant itself. Using proprietary plant cell biology, elicitation technologies, AI-driven development and industrial scale bioreactors, BioHarvest creates highly consistent, bioavailable and patent-protected precision botanics or compounds possessing enhanced potency and purity compared to the original plant, along with the characteristics for commercial scalability.

Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 18, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced the expansion of its collaboration with Tate & Lyle PLC (Tate & Lyle), a global leader in

BioHarvest Sciences Expands Its Joint Sweetener Development Program With Tate & Lyle To Include Multiple Plant-Based Sweetener Molecules

The expanded collaboration builds on the initial agreement signed in 2024 and reflects strong technical progress to date, as well as Tate & Lyle's ambition to equip food and beverage manufacturers with a flexible

BioHarvest Sciences Inc. Common Stock Q1 2026 Earnings Call Summary

Moby summary of BioHarvest Sciences Inc. Common Stock's Q1 2026 earnings call

BioHarvest Sciences Inc (BHST) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...

BioHarvest Sciences Inc (BHST) reports an 8% revenue increase and strategic advancements, despite facing higher net losses and operating expenses.

BioHarvest Sciences Q1 Earnings Call Highlights

BioHarvest Sciences (NASDAQ:BHST) reported higher first-quarter revenue and reiterated its 2026 outlook as management detailed a broader reorganization around two business lines: its direct-to-consumer VINIA products business and its contract development and manufacturing organization, or CDMO, plat

BioHarvest Sciences Inc. (BHST) Q1 2026 Earnings Call Transcript

BioHarvest Sciences Inc. (BHST) Q1 2026 Earnings Call May 14, 2026 8:00 AM EDTCompany ParticipantsZaki Rakib - Co-Founder, CEO, Executive Chairman &...

BioHarvest Sciences Q1 revenue climbs as it expands botanical synthesis pipeline

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported an 8% jump in first quarter revenue as the company advanced several contract development and manufacturing organization (CDMO) projects and expanded its direct-to-consumer wellness business. The company posted first quarter revenue of...